Monday's Underperforming Sectors: Food and Pharmaceuticals
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 13 2025
0mins
Source: NASDAQ.COM
Market Performance: Drug shares are lagging behind the market, down approximately 0.6% overall.
Notable Declines: Tvardi Therapeutics has seen a significant drop of about 84.1%, while Lite Strategy is down by around 14.2%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LITS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LITS
About LITS
Lite Strategy, Inc., formerly MEI Pharma, Inc., is a Litecoin treasury company. The Company accumulates pure LTC through active treasury management and concentrates holdings per share as the ultimate metric of shareholder value. It is a clinical-stage pharmaceutical company focused on the development of differentiated cancer therapies intended to improve outcomes for patients. Its approach to oncology drug development is to evaluate its drug candidates in combination with standard-of-care therapies to overcome known resistance mechanisms and address clear medical needs. The portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3Kd inhibitor. Voruciclib is a selective orally administered CDK9 inhibitor with potential to treat both hematological malignancies and solid tumors. Voruciclib, a selective orally administered inhibitor of CDK9, is in clinical development for acute myeloid leukemia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Davis Commodities Reports $95M Revenue in H1, Up 42.1%
- Significant Revenue Growth: Davis Commodities Ltd reported a revenue of $95 million for the first half ending June 30, marking a 42.1% increase from $66.9 million a year earlier, indicating strong performance in the agricultural commodity trading sector and boosting market confidence.
- Stock Price Surge: Following the earnings report, Davis Commodities' shares jumped 5.6% to $0.25 in pre-market trading, reflecting investor optimism regarding the company's future growth potential.
- Positive Market Reaction: The stock price increase post-earnings release indicates market recognition of Davis Commodities' performance, which may attract more investor interest and further drive the stock price upward.
- Optimistic Industry Outlook: With the ongoing demand for agricultural commodities, the strong earnings report not only enhances Davis Commodities' market position but also potentially provides funding for future expansion and investments.
Continue Reading
Lite Strategy Unveils $25 Million Stock Buyback Initiative
Share Repurchase Program Announcement: Lite Strategy, Inc. (LITS) has authorized a share repurchase program for up to $25 million of its common stock.
Immediate Effectiveness: The repurchase program is effective immediately and allows for shares to be bought back in the open market or through negotiated transactions.
Continue Reading